http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102512436-B
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0e6adc8977de392c55e7e3b7f85a5ea2 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-203 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7076 |
| filingDate | 2011-12-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2013-05-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a6f4e0a68a7bdef29b598bac347b1eca http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b731fa4a29ef4864e087df9e47fb8bec http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_56e6e1ded81e4e1d0ebf615f40253a88 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_349e95c48569ec614966bdbe2635792e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3753e15f818dc7d99be81a693d3a777e http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_67e68b5d395911f1829815daf1e1ef8d |
| publicationDate | 2013-05-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-102512436-B |
| titleOfInvention | Combined drug with synergistic effect and for treating t(11;17) acute promyelocytic leukemia and its application |
| abstract | The invention relates to a combined drug with a synergistic effect and for treating t(11;17) acute promyelocytic leukemia. The combined drug is composed of ATRA and 8-CPT-cAMP. The invention also provides application of the combined drug in preparing drugs treating t(11;17) acute promyelocytic leukemia. The invention has the advantages that: by using the combined drug of the invention, the synergistic effect of two drugs can be exerted, so that the drug resistance of a t(11;17) leukemia cell to ARTA can be reversed, the leukemia cell can be substantially inhibited from growing and be promoted to differentiation and maturation; while significantly improving the curative effects, the combination of the two drugs has no obvious toxic or side effect on normal bone marrow stem cells; and application of the combined drug provided in the invention can overcome the drug resistant defect caused by single use of one drug in prior art. |
| priorityDate | 2011-12-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 131.